Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2303 + CHOP
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
TQB2303 + CHOP is a combination regimen consisting of **TQB2303** (an investigational anti-CD20 monoclonal antibody) plus the established CHOP chemotherapy protocol. CHOP includes **cyclophosphamide** (an alkylating agent), **doxorubicin** (an anthracycline antibiotic), **vincristine** (a vinca alkaloid), and **prednisone** (a corticosteroid). The addition of TQB2303, which is designed to target the CD20 antigen on B cells, is intended to improve therapeutic efficacy in B-cell lymphomas compared with CHOP alone. TQB2303 is developed to be a biosimilar or analog of rituximab and is under clinical investigation primarily for **non-Hodgkin lymphoma** (NHL), particularly **diffuse large B-cell lymphoma** (DLBCL).
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TQB2303 + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2303 + CHOP.